Global Information
회사소개 | 문의 | 비교리스트

하수체 ACTH 과잉분비(쿠싱병) : 파이프라인 리뷰

Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorder) - Drugs in Development, 2021

리서치사 Global Markets Direct
발행일 2021년 12월 상품코드 253635
페이지 정보 영문 43 Pages 배송안내
가격
US $ 2,000 ₩ 2,548,000 PDF (Single user license) help
1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 4,000 ₩ 5,096,000 PDF (Site license) help
동일 사업장 내 모든 분들이 공유하여 사용할 수 있습니다. 이용 인원수에 제한은 없습니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 2부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.
US $ 6,000 ₩ 7,645,000 PDF (Global license) help
동일 기업의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수에 제한은 없으며, 해외 사업장 및 100% 자회사는 동일 기업으로 간주됩니다. PDF 파일은 Copy & Paste가 가능합니다. PDF 내의 컨텐츠 인쇄는 제한이 없으나, 전체보고서에 대한 제본은 원칙적으로 10부까지만 허용되며, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.


하수체 ACTH 과잉분비(쿠싱병) : 파이프라인 리뷰 Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorder) - Drugs in Development, 2021
발행일 : 2021년 12월 페이지 정보 : 영문 43 Pages

본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문목차를 참고해주시기 바랍니다.

쿠싱병은 하수체로부터 부신피질자극호르몬(ACTH)이 과잉 방출된 상태를 가리킵니다. 여드름, 피부 감염증, 요통, 정신적 변화, 행동 변화, 두통 등의 증상을 볼 수 있습니다. 치료에는 외과수술과 방사선요법이 포함됩니다.

하수체 ACTH 과잉분비(쿠싱병)에 대한 치료제 개발 상황에 대해 조사분석했으며, 파이프라인 제품 개요, 임상시험 단계별 제품 개요, 주요 기업 개요, 약제 개요, 파이프라인 제품의 최신 동향, 최신 뉴스와 프레스 릴리스 등에 대한 체계적인 정보를 정리하여 전해드립니다.

목차

서론

하수체 ACTH 과잉분비(쿠싱병) 개요

치료제 개발

  • 파이프라인 제품 : 개요
  • 파이프라인 제품 : 비교 분석

개발중인 치료제 : 기업별

조사중인 치료제 : 대학/연구기관별

파이프라인 제품 개요

  • 후기 단계 제품
  • 임상시험 단계 제품
  • 초기 단계 제품
  • 개발 단계 불명 제품

개발중인 제품 : 기업별

조사중인 제품 : 대학/연구기관별

치료제 개발에 종사하고 있는 기업

  • Alder Biopharmaceuticals Inc.
  • Corcept Therapeutics Incorporated
  • Cortendo AB
  • Cyclacel Pharmaceuticals, Inc.
  • ElexoPharm GmbH
  • Ipsen S.A.
  • Isis Pharmaceuticals, Inc.
  • Novartis AG
  • Orphagen Pharmaceuticals, Inc.
  • Pfizer Inc.

치료제 평가

  • 단일요법 제품의 경우
  • 표적별
  • 작용기서별
  • 투여 경로별
  • 분자 유형별

약제 개요

  • ALD-1613
  • AT-814
  • ATR-101
  • BIM-23A758
  • COR-005
  • CORT-125134
  • ISIS-GCCRRx
  • ketoconazole
  • mifepristone
  • MPP-482
  • osilodrostat
  • pasireotide LAR
  • Peptides to Antagonize ACTH Receptor for Cushing's Syndrome
  • seliciclib
  • Small Molecule to Antagonize Melanocortin Receptor 2 for Cushing's Disease
  • Small Molecules to Antagonize Steroidogenic Factor-1 for Endometriosis, Cancer and Cushing's Disease
  • Small Molecules to Inhibit CYP11B1 for Cushing's Disease and Subclinical Hypercortisolism
  • Small Molecules to Modulate Cryptochrome for Metabolic and CNS Disorders

파이프라인 제품의 최신 동향

휴지 상태 프로젝트

제품 개발 마일스톤

  • 최신 뉴스와 프레스 릴리스

부록

도표

KSA 15.10.29

List of Tables

List of Tables

  • Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products under Development by Universities/Institutes, 2021
  • Products under Development by Companies, 2021
  • Products under Development by Universities/Institutes, 2021
  • Number of Products by Stage and Target, 2021
  • Number of Products by Stage and Mechanism of Action, 2021
  • Number of Products by Stage and Route of Administration, 2021
  • Number of Products by Stage and Molecule Type, 2021
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Crinetics Pharmaceuticals Inc, 2021
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Cyclacel Pharmaceuticals Inc, 2021
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Diurnal Group Plc, 2021
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Recordati SpA, 2021
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Pipeline by Strongbridge Biopharma plc, 2021
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects, 2021
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products, 2021

List of Figures

List of Figures

  • Number of Products under Development for Pituitary ACTH Hypersecretion (Cushing Disease), 2021
  • Number of Products under Development by Companies, 2021
  • Number of Products by Top 10 Targets, 2021
  • Number of Products by Stage and Top 10 Targets, 2021
  • Number of Products by Top 10 Mechanism of Actions, 2021
  • Number of Products by Stage and Top 10 Mechanism of Actions, 2021
  • Number of Products by Routes of Administration, 2021
  • Number of Products by Stage and Routes of Administration, 2021
  • Number of Products by Molecule Types, 2021
  • Number of Products by Stage and Molecule Types, 2021

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease) - Drugs In Development, 2021, provides an overview of the Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline landscape.

Cushing's disease is a condition which results from hypersecretion of adrenocorticotropic hormone (ACTH) due to pituitary gland tumor. Symptoms include acne or skin infections, backache, mental changes (such as depression, anxiety, or changes in behavior), plethora, menstrual disorders, and weight gain. Treatment includes radiation, chemotherapy, and use of certain hormone-inhibiting drugs.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Pituitary ACTH Hypersecretion (Cushing Disease) - Drugs In Development, 2021, provides comprehensive information on the therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Pituitary ACTH Hypersecretion (Cushing Disease) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 1, 1, 1 and 2 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 1 molecule, respectively.

Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders).
  • The pipeline guide reviews pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders)

Reasons to Buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Pituitary ACTH Hypersecretion (Cushing Disease) (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Table of Contents

List of Tables

List of Figures

  • Introduction
  • Global Markets Direct Report Coverage
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Overview
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Companies Involved in Therapeutics Development
  • Crinetics Pharmaceuticals Inc
  • Cyclacel Pharmaceuticals Inc
  • Diurnal Group Plc
  • Recordati SpA
  • Strongbridge Biopharma plc
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Drug Profiles
  • Antisense RNAi Oligonucleotide to Inhibit Pro-Opiomelanocortin for ATCH-Dependent Cushing's syndrome - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • CRN-04894 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • osilodrostat phosphate - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • seliciclib - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Silibinin - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • veldoreotide ER - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Dormant Projects
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Discontinued Products
  • Pituitary ACTH Hypersecretion (Cushing Disease) - Product Development Milestones
  • Featured News & Press Releases
  • Feb 04, 2021: Crinetics Pharmaceuticals lead ACTH antagonist for congenital adrenal hyperplasia and Cushing's disease (CRN04894) advances into phase 1 study
  • Jul 02, 2015: First Patient Dosed in IST of CDK Inhibitor Seliciclib in Cushing's Disease, a Serious Endocrine Disorder
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
Back to Top
전화 문의
F A Q